172 related articles for article (PubMed ID: 20308314)
1. Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing.
Hashizume R; Gupta N; Berger MS; Banerjee A; Prados MD; Ayers-Ringler J; James CD; VandenBerg SR
Neuro Oncol; 2010 Apr; 12(4):366-76. PubMed ID: 20308314
[TBL] [Abstract][Full Text] [Related]
2. Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy.
Dinca EB; Sarkaria JN; Schroeder MA; Carlson BL; Voicu R; Gupta N; Berger MS; James CD
J Neurosurg; 2007 Sep; 107(3):610-6. PubMed ID: 17886562
[TBL] [Abstract][Full Text] [Related]
3. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.
Kitange GJ; Carlson BL; Mladek AC; Decker PA; Schroeder MA; Wu W; Grogan PT; Giannini C; Ballman KV; Buckner JC; James CD; Sarkaria JN
J Neurooncol; 2009 Mar; 92(1):23-31. PubMed ID: 19011762
[TBL] [Abstract][Full Text] [Related]
6. Dual bioluminescence and near-infrared fluorescence monitoring to evaluate spherical nucleic acid nanoconjugate activity in vivo.
Sita TL; Kouri FM; Hurley LA; Merkel TJ; Chalastanis A; May JL; Ghelfi ST; Cole LE; Cayton TC; Barnaby SN; Sprangers AJ; Savalia N; James CD; Lee A; Mirkin CA; Stegh AH
Proc Natl Acad Sci U S A; 2017 Apr; 114(16):4129-4134. PubMed ID: 28373576
[TBL] [Abstract][Full Text] [Related]
7. Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems.
Toren A; Pismenyuk T; Yalon M; Freedman S; Simon AJ; Fisher T; Moshe I; Reichardt JK; Constantini S; Mardor Y; Last D; Guez D; Daniels D; Assoulin M; Mehrian-Shai R
Oncotarget; 2016 Nov; 7(46):74860-74871. PubMed ID: 27556862
[TBL] [Abstract][Full Text] [Related]
8. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
Verreault M; Wehbe M; Strutt D; Masin D; Anantha M; Walker D; Chu F; Backstrom I; Kalra J; Waterhouse D; Yapp DT; Bally MB
J Control Release; 2015 Dec; 220(Pt A):348-357. PubMed ID: 26528901
[TBL] [Abstract][Full Text] [Related]
9. Encapsulation of Temozolomide in a Calixarene Nanocapsule Improves Its Stability and Enhances Its Therapeutic Efficacy against Glioblastoma.
Renziehausen A; Tsiailanis AD; Perryman R; Stylos EK; Chatzigiannis C; O'Neill K; Crook T; Tzakos AG; Syed N
Mol Cancer Ther; 2019 Sep; 18(9):1497-1505. PubMed ID: 31213505
[TBL] [Abstract][Full Text] [Related]
10. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
11. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.
Kitange GJ; Carlson BL; Schroeder MA; Grogan PT; Lamont JD; Decker PA; Wu W; James CD; Sarkaria JN
Neuro Oncol; 2009 Jun; 11(3):281-91. PubMed ID: 18952979
[TBL] [Abstract][Full Text] [Related]
12. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity to temozolomide in brain tumor initiating cells.
Blough MD; Westgate MR; Beauchamp D; Kelly JJ; Stechishin O; Ramirez AL; Weiss S; Cairncross JG
Neuro Oncol; 2010 Jul; 12(7):756-60. PubMed ID: 20388697
[TBL] [Abstract][Full Text] [Related]
14. A human brainstem glioma xenograft model enabled for bioluminescence imaging.
Hashizume R; Ozawa T; Dinca EB; Banerjee A; Prados MD; James CD; Gupta N
J Neurooncol; 2010 Jan; 96(2):151-9. PubMed ID: 19585223
[TBL] [Abstract][Full Text] [Related]
15. Synergy between methionine stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice.
Kokkinakis DM; Hoffman RM; Frenkel EP; Wick JB; Han Q; Xu M; Tan Y; Schold SC
Cancer Res; 2001 May; 61(10):4017-23. PubMed ID: 11358820
[TBL] [Abstract][Full Text] [Related]
16. Convection-enhanced delivery of a synthetic retinoid Am80, loaded into polymeric micelles, prolongs the survival of rats bearing intracranial glioblastoma xenografts.
Yokosawa M; Sonoda Y; Sugiyama S; Saito R; Yamashita Y; Nishihara M; Satoh T; Kumabe T; Yokoyama M; Tominaga T
Tohoku J Exp Med; 2010 Aug; 221(4):257-64. PubMed ID: 20622491
[TBL] [Abstract][Full Text] [Related]
17. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
[TBL] [Abstract][Full Text] [Related]
18. Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthotopic xenografts.
Lefranc F; James S; Camby I; Gaussin JF; Darro F; Brotchi J; Gabius J; Kiss R
J Neurosurg; 2005 Apr; 102(4):706-14. PubMed ID: 15871514
[TBL] [Abstract][Full Text] [Related]
19. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.
Carlson BL; Grogan PT; Mladek AC; Schroeder MA; Kitange GJ; Decker PA; Giannini C; Wu W; Ballman KA; James CD; Sarkaria JN
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):212-9. PubMed ID: 19695438
[TBL] [Abstract][Full Text] [Related]
20. Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide.
López-Valero I; Saiz-Ladera C; Torres S; Hernández-Tiedra S; García-Taboada E; Rodríguez-Fornés F; Barba M; Dávila D; Salvador-Tormo N; Guzmán M; Sepúlveda JM; Sánchez-Gómez P; Lorente M; Velasco G
Biochem Pharmacol; 2018 Nov; 157():266-274. PubMed ID: 30195736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
